229 related articles for article (PubMed ID: 30269333)
1. The histone deacetylase inhibitor nicotinamide exacerbates neurodegeneration in the lactacystin rat model of Parkinson's disease.
Harrison IF; Powell NM; Dexter DT
J Neurochem; 2019 Jan; 148(1):136-156. PubMed ID: 30269333
[TBL] [Abstract][Full Text] [Related]
2. Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of Parkinson's is associated with histone acetylation and up-regulation of neurotrophic factors.
Harrison IF; Crum WR; Vernon AC; Dexter DT
Br J Pharmacol; 2015 Aug; 172(16):4200-15. PubMed ID: 26040297
[TBL] [Abstract][Full Text] [Related]
3. Associated degeneration of ventral tegmental area dopaminergic neurons in the rat nigrostriatal lactacystin model of parkinsonism and their neuroprotection by valproate.
Harrison IF; Anis HK; Dexter DT
Neurosci Lett; 2016 Feb; 614():16-23. PubMed ID: 26742637
[TBL] [Abstract][Full Text] [Related]
4. Pathological histone acetylation in Parkinson's disease: Neuroprotection and inhibition of microglial activation through SIRT 2 inhibition.
Harrison IF; Smith AD; Dexter DT
Neurosci Lett; 2018 Feb; 666():48-57. PubMed ID: 29273397
[TBL] [Abstract][Full Text] [Related]
5. Liposomal-formulated curcumin [Lipocurc™] targeting HDAC (histone deacetylase) prevents apoptosis and improves motor deficits in Park 7 (DJ-1)-knockout rat model of Parkinson's disease: implications for epigenetics-based nanotechnology-driven drug platform.
Chiu S; Terpstra KJ; Bureau Y; Hou J; Raheb H; Cernvosky Z; Badmeav V; Copen J; Husni M; Woodbury-Farina M
J Complement Integr Med; 2013 Nov; 10():. PubMed ID: 24200537
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
Harrison IF; Dexter DT
Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
[TBL] [Abstract][Full Text] [Related]
7. Astrocyte support is important for the compensatory potential of the nigrostriatal system neurons during early neurodegeneration.
Kuter K; Olech Ł; Głowacka U; Paleczna M
J Neurochem; 2019 Jan; 148(1):63-79. PubMed ID: 30295916
[TBL] [Abstract][Full Text] [Related]
8. Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
Komnig D; Dagli TC; Habib P; Zeyen T; Schulz JB; Falkenburger BH
J Neurochem; 2018 Dec; 147(5):678-691. PubMed ID: 30152864
[TBL] [Abstract][Full Text] [Related]
9. Peripheral administration of the Class-IIa HDAC inhibitor MC1568 partially protects against nigrostriatal neurodegeneration in the striatal 6-OHDA rat model of Parkinson's disease.
Mazzocchi M; Goulding SR; Morales-Prieto N; Foley T; Collins LM; Sullivan AM; O'Keeffe GW
Brain Behav Immun; 2022 May; 102():151-160. PubMed ID: 35217173
[TBL] [Abstract][Full Text] [Related]
10. Non-invasive evaluation of nigrostriatal neuropathology in a proteasome inhibitor rodent model of Parkinson's disease.
Vernon AC; Johansson SM; Modo MM
BMC Neurosci; 2010 Jan; 11():1. PubMed ID: 20051106
[TBL] [Abstract][Full Text] [Related]
11. Histone hyperacetylation up-regulates protein kinase Cδ in dopaminergic neurons to induce cell death: relevance to epigenetic mechanisms of neurodegeneration in Parkinson disease.
Jin H; Kanthasamy A; Harischandra DS; Kondru N; Ghosh A; Panicker N; Anantharam V; Rana A; Kanthasamy AG
J Biol Chem; 2014 Dec; 289(50):34743-67. PubMed ID: 25342743
[TBL] [Abstract][Full Text] [Related]
12. A dual inhibitor targeting HMG-CoA reductase and histone deacetylase mitigates neurite degeneration in
Lin CH; Lin HY; Fang JM; Chen CC
Aging (Albany NY); 2020 Nov; 12(24):25581-25598. PubMed ID: 33231564
[TBL] [Abstract][Full Text] [Related]
13. Pedunculopontine cell loss and protein aggregation direct microglia activation in parkinsonian rats.
Elson JL; Yates A; Pienaar IS
Brain Struct Funct; 2016 May; 221(4):2319-41. PubMed ID: 25989851
[TBL] [Abstract][Full Text] [Related]
14. Zonisamide reduces nigrostriatal dopaminergic neurodegeneration in a mouse genetic model of Parkinson's disease.
Sano H; Murata M; Nambu A
J Neurochem; 2015 Jul; 134(2):371-81. PubMed ID: 25857446
[TBL] [Abstract][Full Text] [Related]
15. Rosiglitazone, a PPAR-γ agonist, protects against striatal dopaminergic neurodegeneration induced by 6-OHDA lesions in the substantia nigra of rats.
Lee EY; Lee JE; Park JH; Shin IC; Koh HC
Toxicol Lett; 2012 Sep; 213(3):332-44. PubMed ID: 22842585
[TBL] [Abstract][Full Text] [Related]
16. Temporal-Spatial Profiling of Pedunculopontine Galanin-Cholinergic Neurons in the Lactacystin Rat Model of Parkinson's Disease.
Elson JL; Kochaj R; Reynolds R; Pienaar IS
Neurotox Res; 2018 Jul; 34(1):16-31. PubMed ID: 29218504
[TBL] [Abstract][Full Text] [Related]
17. Zonisamide attenuates lactacystin-induced parkinsonism in mice without affecting system x
Bentea E; Van Liefferinge J; Verbruggen L; Martens K; Kobayashi S; Deneyer L; Demuyser T; Albertini G; Maes K; Sato H; Smolders I; Lewerenz J; Massie A
Exp Neurol; 2017 Apr; 290():15-28. PubMed ID: 28024798
[TBL] [Abstract][Full Text] [Related]
18. Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.
Zhang Z; Li X; Xie WJ; Tuo H; Hintermann S; Jankovic J; Le W
CNS Neurol Disord Drug Targets; 2012 Sep; 11(6):768-73. PubMed ID: 22483304
[TBL] [Abstract][Full Text] [Related]
19. Protective role of SIRT5 against motor deficit and dopaminergic degeneration in MPTP-induced mice model of Parkinson's disease.
Liu L; Peritore C; Ginsberg J; Shih J; Arun S; Donmez G
Behav Brain Res; 2015 Mar; 281():215-21. PubMed ID: 25541039
[TBL] [Abstract][Full Text] [Related]
20. α-synuclein oligomers enhance astrocyte-induced synapse formation through TGF-β1 signaling in a Parkinson's disease model.
Diniz LP; Matias I; Araujo APB; Garcia MN; Barros-Aragão FGQ; Alves-Leon SV; de Souza JM; Foguel D; Figueiredo CP; Braga C; Romão L; Gomes FCA
J Neurochem; 2019 Jul; 150(2):138-157. PubMed ID: 31009074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
